Mace Rothenberg is Director at Tango Therapeutics, Inc. (TNGX). They have made 1 open-market trade across 1 company since 2024, most recently 2026-06-05.
CIK 0001873988
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $74K since 2024, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TNGX | 41,500 | $961K |
Shares reported on the most recent Form 4, priced at the 2026-06-08 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TNGX | BUY | 2024-11-14 | 2024-11-18 | $3.70 | $74K | +6.5% | -24.6% | -34.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.